menu search

Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance

In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vac...

November 3, 2023, 8:30 pm

Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance

In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vac...

November 3, 2023, 8:30 pm

Universal display (oled) q3 earnings beat despite lower revenues

Universal Display's (OLED) top line is affected by lower Royalty and license fee revenues, induced by c...

November 3, 2023, 12:47 pm

Spot etf-induced bitcoin rally isn’t guaranteed to stick: analysts

The allure of a potential spot Bitcoin ETF approval is playing on everyone’s minds. Cointelegraph asked analysts and traders to weigh in on what inv...

November 2, 2023, 5:59 am

Usd/chf consolidates its gains, eyes on fed rate decision, snb’s jordan speech

AUD/USD is consolidating losses below 0.6350, induced by China’s Caixin Manufacturing PMI unexpected ...

November 1, 2023, 5:44 am

Fate therapeutics to webcast conference call reporting third quarter 2023 financial results

SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage ...

October 25, 2023, 8:00 am

Multiple states sue meta platforms for allegedly contributing to youth mental health crisis

The lawsuit claims Meta repeatedly misled the public about the substantial dangers of its platforms and knowingly ...

October 24, 2023, 12:01 pm

Oxford cannabinoid technologies delighted with phase 1 outcome for pain drug

Clarissa Sowemimo-Coker, CEO of Oxford Cannabinoid Technologies Holdings, discusses with Proactive's Thomas Warner the successful completion of a phas...

October 24, 2023, 9:46 am

Will higher input cost hurt l3harris (lhx) in q3 earnings?

L3Harris' (LHX) Q3 results are likely to reflect the impact of inflation-induced higher input costs des...

October 20, 2023, 9:46 am

Bitcoin liquidity on binance plummeted during the etf rumor-induced market rollercoaster: kaiko

Binance has long been the world’s largest cryptocurrency exchange by trading volumes. Still, on Monday, traders looking to buy and sell bitcoin (BTC...

October 17, 2023, 5:59 am

Dax index: dax 30’s tug of war – ecb’s concerns vs. us economic indicators

After the US CPI Report-induced pullback on Thursday, the DAX remains exposed to hawkish Fed chatter an...

October 13, 2023, 5:00 am

Relmada therapeutics to present new preclinical data on its psilocybin program at aasld the liver meeting® 2023

Low-dose psilocybin generated s tatistically significant reduc tions in liver fat content, plasma glucose levels and body weight gain in a mice model ...

October 11, 2023, 8:31 am

3 high yield stocks to diversify your tech-oriented portfolio

After a strong liquidity-induced bull run in the technology sector, it is worth considering reducing co...

October 3, 2023, 3:44 pm

Viatris (vtrs) gets fda nod for pupil dilation reversal agent

Viatris (VTRS) and partner Ocuphire Pharma receive FDA approval for Ryzumvi to treat pharmacologically-induced...

September 28, 2023, 12:02 pm

Medicinova announces results of studies under barda contract to develop mn 166 (ibudilast) as a medical countermeasure against chlorine gas-induced lung injury

LA JOLLA, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) a...

September 27, 2023, 11:00 pm

Viatris and ocuphire pharma get fda green light for eye treatment

Viatris Inc. VTRS, and Ocuphire Pharma Inc. OCUP, +3.08% said Wednesday that the U.S. Food and Drug Administration has approved Ryzumvi to treat the s...

September 27, 2023, 8:21 am

Veru reaches agreement with fda on new phase 3 clinical trial for sabizabulin for broader indication: hospitalized adult patients with any type of viral acute respiratory distress syndrome (ards)

–Reached agreement with FDA on single Phase 3 clinical trial design to expand treatment population to include all hospitalized adult patients with a...

September 26, 2023, 12:30 pm

Natural gas prices forecast: bearish turn amid resolved strike, weather, lower lng demand

U.S. NatGas futures’ traders grapple with global supply changes and weather-induced demand shifts. Th...

September 22, 2023, 12:12 pm

Zyversa therapeutics announces research published in the journal of clinical investigation reinforcing ic 100’s rationale for inhibiting asc specks to attenuate spread of inflammation into surrounding

Patients with chronic kidney disease (“CKD”) exhibit chronic systemic inflammation characterized by increased circulating levels of IL-1β, IL-6, ...

September 22, 2023, 10:35 am

Veru to participate in fireside chat at the 2023 cantor fitzgerald global healthcare conference on september 28th, 2023

MIAMI, FL, Sept. 20, 2023 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel m...

September 20, 2023, 12:30 pm


Search within

Pages Search Results: